Historical Valuation
Lexaria Bioscience Corp (LEXX) is now in the Undervalued zone, suggesting that its current forward PS ratio of 20.75 is considered Undervalued compared with the five-year average of -3.32. The fair price of Lexaria Bioscience Corp (LEXX) is between 3.27 to 4.82 according to relative valuation methord. Compared to the current price of 0.75 USD , Lexaria Bioscience Corp is Undervalued By 77.21%.
Relative Value
Fair Zone
3.27-4.82
Current Price：0.75
77.21%
Undervalued
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Lexaria Bioscience Corp (LEXX) has a current Price-to-Book (P/B) ratio of 4.28. Compared to its 3-year average P/B ratio of 3.79 , the current P/B ratio is approximately 13.04% higher. Relative to its 5-year average P/B ratio of 3.36, the current P/B ratio is about 27.51% higher. Lexaria Bioscience Corp (LEXX) has a Forward Free Cash Flow (FCF) yield of approximately -64.36%. Compared to its 3-year average FCF yield of -37.12%, the current FCF yield is approximately 73.37% lower. Relative to its 5-year average FCF yield of -30.35% , the current FCF yield is about 112.02% lower.
P/B
Median3y
3.79
Median5y
3.36
FCF Yield
Median3y
-37.12
Median5y
-30.35
Competitors Valuation Multiple
AI Analysis for LEXX
The average P/S ratio for LEXX competitors is 331.34, providing a benchmark for relative valuation. Lexaria Bioscience Corp Corp (LEXX.O) exhibits a P/S ratio of 20.75, which is -93.74% above the industry average. Given its robust revenue growth of 107.14%, this premium appears sustainable.
Performance Decomposition
AI Analysis for LEXX
1Y
3Y
5Y
Market capitalization of LEXX increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of LEXX in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is LEXX currently overvalued or undervalued?
Lexaria Bioscience Corp (LEXX) is now in the Undervalued zone, suggesting that its current forward PS ratio of 20.75 is considered Undervalued compared with the five-year average of -3.32. The fair price of Lexaria Bioscience Corp (LEXX) is between 3.27 to 4.82 according to relative valuation methord. Compared to the current price of 0.75 USD , Lexaria Bioscience Corp is Undervalued By 77.21% .
What is Lexaria Bioscience Corp (LEXX) fair value?
LEXX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Lexaria Bioscience Corp (LEXX) is between 3.27 to 4.82 according to relative valuation methord.
How does LEXX's valuation metrics compare to the industry average?
The average P/S ratio for LEXX's competitors is 331.34, providing a benchmark for relative valuation. Lexaria Bioscience Corp Corp (LEXX) exhibits a P/S ratio of 20.75, which is -93.74% above the industry average. Given its robust revenue growth of 107.14%, this premium appears sustainable.
What is the current P/B ratio for Lexaria Bioscience Corp (LEXX) as of Jan 10 2026?
As of Jan 10 2026, Lexaria Bioscience Corp (LEXX) has a P/B ratio of 4.28. This indicates that the market values LEXX at 4.28 times its book value.
What is the current FCF Yield for Lexaria Bioscience Corp (LEXX) as of Jan 10 2026?
As of Jan 10 2026, Lexaria Bioscience Corp (LEXX) has a FCF Yield of -64.36%. This means that for every dollar of Lexaria Bioscience Corp’s market capitalization, the company generates -64.36 cents in free cash flow.
What is the current Forward P/E ratio for Lexaria Bioscience Corp (LEXX) as of Jan 10 2026?
As of Jan 10 2026, Lexaria Bioscience Corp (LEXX) has a Forward P/E ratio of -1.64. This means the market is willing to pay $-1.64 for every dollar of Lexaria Bioscience Corp’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Lexaria Bioscience Corp (LEXX) as of Jan 10 2026?
As of Jan 10 2026, Lexaria Bioscience Corp (LEXX) has a Forward P/S ratio of 20.75. This means the market is valuing LEXX at $20.75 for every dollar of expected revenue over the next 12 months.